ABS-0871

Infographic highlighting Setara’s $90 million financing to advance STAR-0871 for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, featuring neurological and bladder illustrations and the continuation of Actio’s development pipeline following the Jazz acquisition.

Pharma & Biotech

Setara Biosciences raises $90m to advance STAR-0871 for CMT2C and overactive bladder after Jazz acquisition

by Pallavi Madhiraju
November 1, 2026
0 Comments

Setara raises $90m to advance STAR-0871 for CMT2C and overactive bladder, carrying forward Actio’s pipeline after the Jazz acquisition.

Read More